3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma
4
Glioblastoma
2
Central Nervous System Neoplasms
2
Brain Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Thymus Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Kaposi
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Radiation Injuries
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pharyngeal Neoplasms
1
Penile Neoplasms
1
Parotid Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Interventions
interferon gamma-1b
1
Oncolytic Virotherapy
1
Interferon-gamma
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Glandular and Epithelial
×
Immunotherapy
×
Sarcoma
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled